Nephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review

Ramucirumab is a human immunoglobulin G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 and is used for the treatment of metastatic or inoperable gastric, colorectal, and non-small cell lung cancers. However, ramucirumab can result in renal adverse events, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Teruhiro, Kawasoe, Kentaro, Tonooka, Akiko, Ohta, Akihito, Nitta, Kosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635164/
https://www.ncbi.nlm.nih.gov/pubmed/31277139
http://dx.doi.org/10.1097/MD.0000000000016236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635164/
https://www.ncbi.nlm.nih.gov/pubmed/31277139
http://dx.doi.org/10.1097/MD.0000000000016236

Ejemplares similares